How to make the best of NLRP3 inhibitors in patients with COVID-19?
| Errataetall: |
CommentOn: Eur J Clin Pharmacol. 2023 Jun;79(6):723-751. - PMID 37081137 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:79 |
|---|---|
| Enthalten in: |
European journal of clinical pharmacology - 79(2023), 8 vom: 01. Aug., Seite 1143-1144 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Kow, Chia Siang [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Comment |
|---|
| Anmerkungen: |
Date Completed 23.10.2023 Date Revised 03.04.2024 published: Print-Electronic CommentOn: Eur J Clin Pharmacol. 2023 Jun;79(6):723-751. - PMID 37081137 Citation Status MEDLINE |
|---|
| doi: |
10.1007/s00228-023-03518-z |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM357961064 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM357961064 | ||
| 003 | DE-627 | ||
| 005 | 20240403234846.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s00228-023-03518-z |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1362.xml |
| 035 | |a (DE-627)NLM357961064 | ||
| 035 | |a (NLM)37294339 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Kow, Chia Siang |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a How to make the best of NLRP3 inhibitors in patients with COVID-19? |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 23.10.2023 | ||
| 500 | |a Date Revised 03.04.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a CommentOn: Eur J Clin Pharmacol. 2023 Jun;79(6):723-751. - PMID 37081137 | ||
| 500 | |a Citation Status MEDLINE | ||
| 650 | 4 | |a Letter | |
| 650 | 4 | |a Comment | |
| 650 | 7 | |a NLR Family, Pyrin Domain-Containing 3 Protein |2 NLM | |
| 650 | 7 | |a Inflammasomes |2 NLM | |
| 700 | 1 | |a Ramachandram, Dinesh Sangarran |e verfasserin |4 aut | |
| 700 | 1 | |a Hasan, Syed Shahzad |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t European journal of clinical pharmacology |d 1971 |g 79(2023), 8 vom: 01. Aug., Seite 1143-1144 |w (DE-627)NLM000099538 |x 1432-1041 |7 nnns |
| 773 | 1 | 8 | |g volume:79 |g year:2023 |g number:8 |g day:01 |g month:08 |g pages:1143-1144 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s00228-023-03518-z |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 79 |j 2023 |e 8 |b 01 |c 08 |h 1143-1144 | ||